Description: This randomized clinical trial from the GRADE study compares the risk of hypoglycemia among people with type 2 diabetes taking metformin who added glargine, glimepiride, liraglutide, or sitagliptin. It shows that hypoglycemia was most common with glimepiride, less frequent with glargine, and least common with liraglutide and sitagliptin, highlighting important safety differences between common diabetes therapies.

Citation: Seaquist, E. R., Phillips, L. S., Ghosh, A., Baker, C., Bergenstal, R. M., Crandall, J. P., Goland, R. S., Gramzinski, M. R., Hox, S. H., Hsia, D. S., Johnson, M. L., Lachin, J. M., Raskin, P., Valencia, W. M., Waltje, A. H., Younes, N., & GRADE Research Group (2024). Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial. PloS one, 19(11), e0309907. https://doi.org/10.1371/journal.pone.0309907